FOSUN PHARMA (600196.SH) Subsidiary Receives Approval for Drug Registration Application

Stock News

Sep 24

FOSUN PHARMA (600196.SH) announced that its controlling subsidiary Fosun Kerry (Shanghai) Biotechnology Co., Ltd. ("Fosun Kerry") has recently received approval from the National Medical Products Administration for its drug registration application of Brexucabtagene Autoleucel Injection (project code: FKC889, application registration category: therapeutic biological product category 3.2, hereinafter referred to as "the Product"). The indication for this application is for the treatment of adult patients with relapsed or refractory precursor B-cell acute lymphoblastic leukemia (ALL).

The Product is a CD19-targeted CAR-T cell therapy product that Fosun Kerry developed and obtained authorization for development and localized production in China (including Hong Kong and Macau) based on Tecartus introduced from Kite Pharma, Inc. (a controlling subsidiary of Gilead Sciences, Inc.) through technology transfer. Tecartus was approved for market launch in the United States and Europe in July and December 2020, respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1155587215"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1155587215\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1155587215?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-24 17:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1155587215","market":"fut","top_or_hot":-1,"title":"FOSUN PHARMA (600196.SH) Subsidiary Receives Approval for Drug Registration Application","media":"Stock News","content":"<p>FOSUN PHARMA (600196.SH) announced that its controlling subsidiary Fosun Kerry (Shanghai) Biotechnology Co., Ltd. (\"Fosun Kerry\") has recently received approval from the National Medical Products Administration for its drug registration application of Brexucabtagene Autoleucel Injection (project code: FKC889, application registration category: therapeutic biological product category 3.2, hereinafter referred to as \"the Product\"). The indication for this application is for the treatment of adult patients with relapsed or refractory precursor B-cell acute lymphoblastic leukemia (ALL).</p>\n<p>The Product is a CD19-targeted CAR-T cell therapy product that Fosun Kerry developed and obtained authorization for development and localized production in China (including Hong Kong and Macau) based on Tecartus introduced from Kite Pharma, Inc. (a controlling subsidiary of Gilead Sciences, Inc.) through technology transfer. Tecartus was approved for market launch in the United States and Europe in July and December 2020, respectively.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FOSUN PHARMA (600196.SH) Subsidiary Receives Approval for Drug Registration Application</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFOSUN PHARMA (600196.SH) Subsidiary Receives Approval for Drug Registration Application\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-09-24 17:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>FOSUN PHARMA (600196.SH) announced that its controlling subsidiary Fosun Kerry (Shanghai) Biotechnology Co., Ltd. (\"Fosun Kerry\") has recently received approval from the National Medical Products Administration for its drug registration application of Brexucabtagene Autoleucel Injection (project code: FKC889, application registration category: therapeutic biological product category 3.2, hereinafter referred to as \"the Product\"). The indication for this application is for the treatment of adult patients with relapsed or refractory precursor B-cell acute lymphoblastic leukemia (ALL).</p>\n<p>The Product is a CD19-targeted CAR-T cell therapy product that Fosun Kerry developed and obtained authorization for development and localized production in China (including Hong Kong and Macau) based on Tecartus introduced from Kite Pharma, Inc. (a controlling subsidiary of Gilead Sciences, Inc.) through technology transfer. Tecartus was approved for market launch in the United States and Europe in July and December 2020, respectively.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0012","symbol_name":"证金概念","start_time":0,"source_url":"","article_id":"1155587215","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1155587215","pubTimestamp":1758705658,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"FOSUN PHARMA (600196.SH) announced that its controlling subsidiary Fosun Kerry (Shanghai) Biotechnology Co., Ltd. (\"Fosun Kerry\") has recently received approval from the National Medical Products...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600196":"复星医药","BK0012":"证金概念","BK1593":"医美概念股","BK1191":"制药","02196":"复星医药","BK0196":"行业龙头","BK0175":"白马股","BK0187":"一线龙头","BK0060":"抗癌","BK0028":"国家队","BK0239":"医药制造","BK0183":"MSCI概念","BK0096":"民营医院","BK0188":"融资融券","BK1515":"抗疫概念"},"translate_title":"复星医药（600196.SH）子公司药品注册申请获批件","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":1,"02196":1},"content_text":"FOSUN PHARMA (600196.SH) announced that its controlling subsidiary Fosun Kerry (Shanghai) Biotechnology Co., Ltd. (\"Fosun Kerry\") has recently received approval from the National Medical Products Administration for its drug registration application of Brexucabtagene Autoleucel Injection (project code: FKC889, application registration category: therapeutic biological product category 3.2, hereinafter referred to as \"the Product\"). The indication for this application is for the treatment of adult patients with relapsed or refractory precursor B-cell acute lymphoblastic leukemia (ALL).\nThe Product is a CD19-targeted CAR-T cell therapy product that Fosun Kerry developed and obtained authorization for development and localized production in China (including Hong Kong and Macau) based on Tecartus introduced from Kite Pharma, Inc. (a controlling subsidiary of Gilead Sciences, Inc.) through technology transfer. Tecartus was approved for market launch in the United States and Europe in July and December 2020, respectively.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}